Gemtesa

Active Ingredient(s): Vibegron
FDA Approved: * December 23, 2020
Pharm Company: * UROVANT
Category: Urinary System

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Gemtesa Overview

Vibegron, sold under the brand name Gemtesa, is a medication for the treatment of overactive bladder.[1][2][3] Vibegron (other names: RVT-901; MK4618; KRP114V; URO-901) is a selective beta 3 adrenergic receptor agonist. The most common side effects include headache, urinary tract infection, common cold, diarrhea, nausea, and upper respiratory tract infection.[2] It was approved for medical use in the United States in December 202...

Read more Gemtesa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Vibegron

Recent Gemtesa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Vibegron
  • Tablet: 75mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Vibegron or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 20 April 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA